38 patents
Utility
Systems and methods for producing sterile injection devices
12 Sep 23
The present disclosure provides novel processes for providing sterile, pre-filled syringes or injection devices for pharmaceutical compositions, including protein and biopharmaceutical formulations.
Wendy Shieu, Gerald Llorach
Filed: 21 May 21
Utility
Stable protein compositions and methods of their use
21 Feb 23
The present invention is directed to compositions and methods for stabilizing a protein without a surfactant.
Jun Liu, Mark Manning, Isaias Prado
Filed: 28 Oct 16
Utility
Method of filling a container with no headspace
14 Feb 23
The present invention is directed to methods for filling a container wherein the filled container has no headspace.
John Ogez, Jun Liu, Wenchang Ji, Patrick Daniel Begley, Isaias Prado, Mark Manning
Filed: 17 Jun 21
Utility
Stable aqueous formulations of aflibercept
30 Aug 22
A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of aflibercept, wherein the formulation is free of organic co-solvent and/or free of buffer; methods for making such a formulation; and methods of using such a formulation.
Jun Liu, Mark Manning, Sekhar R. Kanapuram
Filed: 10 Sep 19
Utility
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
2 Aug 22
The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (NAFLD) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective PPARγ agonist, INT131 and optionally vitamin E or compositions thereof.
Christos Mantzoros
Filed: 25 Jun 20
Utility
Methods for making recombinant proteins
26 Jul 22
The present invention provides methods and compositions for making proteins, preferably antibodies, more preferably anti-tumor necrosis factor alpha antibodies, and most preferably adalimumab.
Elzbieta Wiktoria Puchacz
Filed: 9 Sep 19
Utility
PPARy agonist for treatment of progressive supranuclear palsy
22 Feb 22
Barbara Finck, David E. Weinstein, Sarita K. Jain
Filed: 3 Apr 18
Utility
High concentration formulations of adalimumab
25 Jan 22
The present invention relates to aqueous pharmaceutical compositions comprising a high concentration (i.e., greater than 50 milligrams per milliliter) of adalimumab (including antibody proteins considered or intended as “biosimilar” or “bio-better” variants of commercially available adalimumab) suitable for long-term storage, and methods of manufacture of the compositions; methods of their administration; and articles containing the same.
Mark Manning, Ryan Erik Holcomb
Filed: 28 Oct 16
Utility
Etanercept formulations stabilized with metal ions
5 Oct 21
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Brian Murphy
Filed: 31 Oct 17
Utility
Etanercept formulations stabilized with amino acids
28 Sep 21
The invention provides stabilized aqueous pharmaceutical etanercept compositions stabilized with an amino acid and suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Brian Murphy
Filed: 21 Mar 19
Utility
Method of filling a container with no headspace
27 Jul 21
The present invention is directed to methods for filling a container wherein the filled container has no headspace.
John Ogez, Jun Liu, Wenchang Ji, Patrick Daniel Begley, Isaias Prado, Mark Manning
Filed: 20 Apr 17
Utility
Etanercept formulations stabilized with sodium chloride
11 May 21
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Brian Murphy
Filed: 28 Jun 19
Utility
Method of manufacturing a protein by perfusion in media with a low amino acid concentration
11 May 21
Perfusion media are disclosed providing excellent cell density, titer and product quality for production of a therapeutic protein in a perfusion process.
Ela Puchacz, James Russell Grove
Filed: 13 Aug 18
Utility
Correctly folded etanercept in high purity and excellent yield
11 May 21
A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided.
Tsutomu Arakawa, Douglas Farrar
Filed: 29 Sep 17
Utility
Method of reducing formation of etanercept aggregates or fragments
27 Apr 21
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Brian Murphy
Filed: 14 Jun 19
Utility
Correctly folded etanercept composition
13 Apr 21
Production of etanercept using perfusion methods achieves attractive yields of properly folded protein.
Ela Puchacz, James Russell Grove
Filed: 30 Jun 15
Utility
Correctly folded etanercept in high purity and excellent yield
23 Mar 21
A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided.
Tsutomu Arakawa, Douglas Farrar
Filed: 17 Jun 19
Utility
Correctly folded etanercept in high purity and excellent yield
23 Mar 21
A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided.
Tsutomu Arakawa, Douglas Farrar
Filed: 17 Jun 19
Utility
Correctly folded etanercept in high purity and excellent yield
23 Mar 21
A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided.
Tsutomu Arakawa, Douglas Farrar
Filed: 17 Jun 19
Utility
Correctly folded etanercept in high purity and excellent yield
16 Mar 21
A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided.
Tsutomu Arakawa, Douglas Farrar
Filed: 17 Jun 19